相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Potential therapeutic effects of mTOR inhibition in atherosclerosis
Ammar Kurdi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
Christopher Southan et al.
NUCLEIC ACIDS RESEARCH (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Enzymes
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Experimental design and analysis and their reporting: new guidance for publication in BJP
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP
John C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Autophagy in Vascular Disease
Guido R. Y. De Meyer et al.
CIRCULATION RESEARCH (2015)
Cellular and molecular effects of the mTOR inhibitor everolimus
Uttara Saran et al.
CLINICAL SCIENCE (2015)
mTOR: a pharmacologic target for autophagy regulation
Young Chul Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Sylvie M. Guichard et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Guang Yang et al.
CELL REPORTS (2015)
mTOR inhibition: A promising strategy for stabilization of atherosclerotic plaques
Wim Martinet et al.
ATHEROSCLEROSIS (2014)
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
Siming Li et al.
BMC CANCER (2014)
Historical landmarks of autophagy research
Yoshinori Ohsumi
CELL RESEARCH (2014)
Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling
Mari Masuda et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
Eva Juengel et al.
MOLECULAR CANCER (2014)
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Nikhil Wagle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Novel Murine Model of Hypertrophic Scarring Using Subcutaneous Infusion of Bleomycin
Alexander M. Cameron et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2014)
Selective Inhibition of PI3K/Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque
Chungang Zhai et al.
PLOS ONE (2014)
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Burhan Hassan et al.
ONCOTARGET (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Immunohistochemical analysis of macroautophagy Recommendations and limitations
Wim Martinet et al.
AUTOPHAGY (2013)
Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers
Sang-Oh Yoon et al.
CURRENT BIOLOGY (2013)
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W. Lamming et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Assessment of Mitochondrial Biogenesis and mTORC1 Signaling During Chronic Rapamycin Feeding in Male and Female Mice
Joshua C. Drake et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2013)
ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase
Ryan C. Russell et al.
NATURE CELL BIOLOGY (2013)
The role of autophagy in neurodegenerative disease
Ralph A. Nixon
NATURE MEDICINE (2013)
Regulation and Function of Uncoordinated-51 Like Kinase Proteins
Edmond Y. Chan
ANTIOXIDANTS & REDOX SIGNALING (2012)
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells
Eva Juengel et al.
CANCER LETTERS (2012)
Macrophage Autophagy Plays a Protective Role in Advanced Atherosclerosis
Xianghai Liao et al.
CELL METABOLISM (2012)
Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury
Shunsaku Nakagawa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
The requirement of uncoordinated 51-like kinase 1 (ULK1) and ULK2 in the regulation of autophagy
Eun-Ju Lee et al.
AUTOPHAGY (2011)
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line
Igor Tsaur et al.
CANCER LETTERS (2011)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Joungmok Kim et al.
NATURE CELL BIOLOGY (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Mechanisms of mTOR inhibitor resistance in cancer therapy
Jennifer S. Carew et al.
TARGETED ONCOLOGY (2011)
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Ryan J. O. Dowling et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Regulation of cell migration by mTOR is mediated through changes in p27(Kip1) phosphorylation
T. Cooper Woods
CELL CYCLE (2010)
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
Jonathan H. Fox et al.
MOLECULAR NEURODEGENERATION (2010)
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
Terence O'Reilly et al.
TRANSLATIONAL ONCOLOGY (2010)
RAD001 (everolimus) induces autophagy in acute lymphoblastic leukemia
Roman Crazzolara et al.
AUTOPHAGY (2009)
ULK1•ATG13•FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
Ian G. Ganley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia
Marc A. Mueller et al.
ATHEROSCLEROSIS (2008)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Selective clearance of macrophages in atherosclerotic plaques by autophagy
Stefan Verheye et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Potential therapeutic applications of autophagy
David C. Rubinsztein et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker
N Mizushima et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients
K Budde et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Sirolimus: Its discovery, biological properties, and mechanism of action
SN Sehgal
TRANSPLANTATION PROCEEDINGS (2003)
Solubilization of rapamycin
P Simamora et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2001)
分享论文
